Trump’s Medicaid Drug Price Promise Faces Delays and Opacity One Year Later

One year after President Trump vowed to reduce prescription drug costs for Medicaid beneficiaries, the administration’s initiative remains in development, shrouded in uncertainty and lacking transparency regarding which medications will be discounted.

During a September 30 event in the Oval Office, Trump announced a voluntary agreement with Pfizer to align U.S. drug prices with those in other wealthy nations, a model the president has described as a “most favored nation” approach. He stated that Pfizer committed to offering its entire prescription drug portfolio to Medicaid at these reduced rates, predicting a significant impact on program costs. Trump anticipated that other pharmaceutical manufacturers would follow suit.

Since that initial announcement, the White House reports that 26 pharmaceutical companies have signed similar agreements. However, the specific terms of these contracts have not been disclosed to the public.

Medicaid serves approximately 66 million Americans. According to data from the nonpartisan Kaiser Family Foundation, net spending on prescription drugs within the program increased by 46% between 2019 and 2024, reaching $46 billion in taxpayer expenditures that year.

Despite the president’s claims of success, turning the pledge into a functional program has proven difficult. The initiative depends on voluntary participation from both drug manufacturers and individual states. This structure means the actual number of discounted drugs and eligible patients may fall short of the administration’s original projections.

Trump also launched TrumpRx, an online platform allowing consumers to access drug discounts if they opt out of using health insurance. Previous reporting indicated that the selection of drugs on this site is limited, and many consumers may find better rates through their insurance copays.

Because the administration has refused to release the underlying pharmaceutical agreements, it remains unclear whether participating companies are required to offer all their medications to Medicaid or if the discounts will apply only to a subset of drugs. Consequently, the full scope of the program’s benefits remains undefined.